Virtu Financial LLC Invests $62,000 in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI)

Virtu Financial LLC purchased a new stake in shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 45,404 shares of the company’s stock, valued at approximately $62,000. Virtu Financial LLC owned 0.08% of Rani Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Janney Montgomery Scott LLC purchased a new position in Rani Therapeutics during the 4th quarter valued at about $37,000. Geode Capital Management LLC increased its holdings in Rani Therapeutics by 14.3% during the third quarter. Geode Capital Management LLC now owns 172,261 shares of the company’s stock valued at $372,000 after buying an additional 21,527 shares during the period. Finally, Stifel Financial Corp raised its stake in Rani Therapeutics by 100.4% in the third quarter. Stifel Financial Corp now owns 269,768 shares of the company’s stock worth $583,000 after buying an additional 135,148 shares in the last quarter. 30.19% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

RANI has been the topic of several recent research reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $9.00 target price on shares of Rani Therapeutics in a research report on Wednesday, February 26th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Rani Therapeutics in a research report on Friday, February 7th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $12.33.

Rani Therapeutics Trading Down 7.4 %

Shares of NASDAQ:RANI opened at $1.26 on Tuesday. The business’s 50-day moving average is $1.51 and its 200 day moving average is $1.83. The company has a debt-to-equity ratio of 2.34, a current ratio of 1.60 and a quick ratio of 1.60. Rani Therapeutics Holdings, Inc. has a 1 year low of $1.24 and a 1 year high of $8.75. The firm has a market capitalization of $72.18 million, a P/E ratio of -1.19 and a beta of 0.14.

Rani Therapeutics (NASDAQ:RANI) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). On average, research analysts predict that Rani Therapeutics Holdings, Inc. will post -1.01 earnings per share for the current fiscal year.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.